Alpha 2.0
Login Register
» Authors » Florian Stehling

Florian Stehling

Explore the profile of Florian Stehling including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 75
Citations 487
Followers 0
Related Specialties
Pulmonary Medicine
Pediatrics
Neurology
Top 10 Co-Authors
Uwe Mellies
Sivagurunathan Sutharsan
Margarete Olivier
Matthias Welsner
Christian Taube
Mathis Steindor
Cordula Koerner-Rettberg
Christian Dohna-Schwake
Wolfgang Gruber
Stefanie Dillenhoefer
Published In
Pediatr Pulmonol
BMC Pulm Med
Klin Padiatr
Am J Respir Crit Care Med
Eur J Pediatr
Affiliations
Soon will be listed here.
Recent Articles
21.
ABCA3-related interstitial lung disease beyond infancy
Li Y, Seidl E, Knoflach K, Gothe F, Forstner M, Michel K, et al.
Thorax . 2023 Feb; 78(6):587-595. PMID: 36808083
Background: The majority of patients with childhood interstitial lung disease (chILD) caused by pathogenic variants in ATP binding cassette subfamily A member 3 (ABCA3) develop severe respiratory insufficiency within their...
22.
Epidemiological trends in nontuberculous mycobacterial infection among people with cystic fibrosis in Germany
Steindor M, Hafkemeyer S, Ruckes C, Stehling F, Naehrlich L, Ringshausen F
Int J Infect Dis . 2023 Feb; 129:32-39. PMID: 36736578
Objectives: People with cystic fibrosis (pwCF) are at risk for infection with nontuberculous mycobacteria (NTM). The epidemiology and screening practice of NTM among pwCF in Germany are largely unknown and...
23.
Biofilm infection of a central venous port-catheter caused by Mycobacterium avium complex in an immunocompetent child with cystic fibrosis
Kavvalou A, Stehling F, Tschiedel E, Kehrmann J, Walkenfort B, Hasenberg M, et al.
BMC Infect Dis . 2022 Dec; 22(1):921. PMID: 36494632
Background: Mycobacterium (M.) chimaera is a non-tuberculous mycobacterium (NTM) that belongs to M. avium complex (MAC). In patients with cystic fibrosis (CF), MAC can cause bronchopulmonary infections that can be...
24.
Next Generation Sequencing of Free Microbial DNA for Rapid Identification of Pathogens in Critically Ill Children with Systemic Inflammatory Response Syndrome (SIRS)
Goretzki S, Schafer M, Dogan B, Bruns N, Tschiedel E, Rath P, et al.
Front Biosci (Landmark Ed) . 2022 Dec; 27(11):302. PMID: 36472101
Background: Infections, major surgeries, and hyperinflammatory syndromes are known to trigger Systemic Inflammatory Response Syndrome (SIRS). Discrimination between infectious and noninfectious inflammation often poses a challenge in chronically ill patients...
25.
Obstructive sleep apnea and nocturnal hypoxemia in adult patients with cystic fibrosis
Welsner M, Dietz-Terjung S, Stehling F, Schulte T, Niehammer U, Gahbiche F, et al.
BMC Pulm Med . 2022 Nov; 22(1):446. PMID: 36437445
Background: Obstructive sleep apnea (OSA), nocturnal hypoxemia and excessive daytime sleepiness (EDS) are common comorbidities in people with cystic fibrosis (pwCF). Most of the data showing this originates from children...
26.
Barriers for Sports and Exercise Participation and Corresponding Barrier Management in Cystic Fibrosis
Dillenhoefer S, Stehling F, Welsner M, Schlegtendal A, Sutharsan S, Olivier M, et al.
Int J Environ Res Public Health . 2022 Oct; 19(20). PMID: 36293733
Background: Nowadays physical activity (PA)/exercise is an important component of cystic fibrosis (CF) therapy. The aim of the study was to assess the barriers to PA and the barrier management...
27.
Phenotypic spectrum in recessive STING-associated vasculopathy with onset in infancy: Four novel cases and analysis of previously reported cases
Wan R, Fander J, Zakaraia I, Lee-Kirsch M, Wolf C, Lucas N, et al.
Front Immunol . 2022 Oct; 13:1029423. PMID: 36275728
Gain-of-function variants in the stimulator of interferon response cGAMP interactor 1 () gene cause STING-Associated Vasculopathy with onset in Infancy (SAVI). Previously, only heterozygous and mostly variants have been reported...
28.
Cough suppression and HRQoL in adult people with cystic fibrosis: an unexplored correlation
Niehammer U, Steindor M, Strassburg S, Sutharsan S, Taube C, Welsner M, et al.
Health Qual Life Outcomes . 2022 Oct; 20(1):141. PMID: 36203159
Background: Cough suppression assessed by embarrassment about coughing has been shown in adolescents with cystic fibrosis (CF) and negatively affects health-related quality of life (HRQoL) and clinical indicators of disease...
29.
Randomized controlled phase 2 trial of hydroxychloroquine in childhood interstitial lung disease
Griese M, Kappler M, Stehling F, Schulze J, Baden W, Koerner-Rettberg C, et al.
Orphanet J Rare Dis . 2022 Jul; 17(1):289. PMID: 35871071
Background: No results of controlled trials are available for any of the few treatments offered to children with interstitial lung diseases (chILD). We evaluated hydroxychloroquine (HCQ) in a phase 2,...
30.
Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous for and a Minimal Function Mutation: A Phase 3b, Randomized, Placebo-controlled Study
Mall M, Brugha R, Gartner S, Legg J, Moeller A, Mondejar-Lopez P, et al.
Am J Respir Crit Care Med . 2022 Jul; 206(11):1361-1369. PMID: 35816621
The triple-combination regimen elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) was shown to be safe and efficacious in children aged 6 through 11 years with cystic fibrosis and at least one allele in a phase...